2018

Haase VH, Chertow GM, Block GA, et al. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2018 Apr. E-pub.
Publication

2017

Gilbertson DT, Hu Y, Peng Y, Maroni BJ, Wetmore JB. Variability in Hemoglobin Levels in Hemodialysis Patients in the Current Era: A Retrospective Cohort Study. Clinical Nephrology. 2017 Nov; 88:254-265.
Publication

Martin ER, Smith MT, Maroni BJ, et al. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. Am J Nephrol. 2017 Mar;45(5):380-388.
Publication

2016

Pergola PE, Spinowitz BS, Hartman CS, et al. Vadadustat, a Novel Oral HIF Stabilizer, Provides Effective Anemia Treatment in Nondialysis-Dependent Chronic Kidney Disease. Kidney International. 2016 Nov; 90(5):1115–1122.
Publication

Luo J, Jensen DE, Maroni BJ, et al. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients. American Journal of Kidney Diseases. 2016 Nov;68(5):763-771.
Publication

Sibbel S, Maroni BJ, Brunelli SM. The Effect of Altitude on Erythropoiesis-Stimulating Agent Dose, Hemoglobin Level, and Mortality in Hemodialysis Patients. J Nephrol. 2016 Sept.
Publication

Vadadustat is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.